NO332848B1 - Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer. - Google Patents

Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer. Download PDF

Info

Publication number: NO332848B1
Authority: NO; Norway
Prior art keywords: formulation according; aerosol formulation; amount; weight; excipient
Prior art date: 2001-03-30

Application number

NO20034323A

Other languages

English (en)

Norwegian (no)

Other versions

NO20034323L (no

NO20034323D0 (no

Inventor

Rudi Mueller-Walz

Carsten Niederlander

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2003-09-26

Publication date

2013-01-21

2003-09-26 Application filed by Jagotec Ag filed Critical Jagotec Ag

2003-09-26 Publication of NO20034323L publication Critical patent/NO20034323L/no

2003-09-26 Publication of NO20034323D0 publication Critical patent/NO20034323D0/no

2013-01-21 Publication of NO332848B1 publication Critical patent/NO332848B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 194
238000009472 formulation Methods 0.000 title claims abstract description 158
239000000443 aerosol Substances 0.000 title claims abstract description 105
239000000546 pharmaceutical excipient Substances 0.000 title claims description 64
238000004519 manufacturing process Methods 0.000 title claims description 7
239000000725 suspension Substances 0.000 claims abstract description 47
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical class CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 26
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 15
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 14
235000021355 Stearic acid Nutrition 0.000 claims abstract description 14
229910052791 calcium Inorganic materials 0.000 claims abstract description 14
239000011575 calcium Substances 0.000 claims abstract description 14
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 14
239000008117 stearic acid Chemical class 0.000 claims abstract description 14
150000003751 zinc Chemical class 0.000 claims abstract description 14
235000021314 Palmitic acid Nutrition 0.000 claims abstract description 13
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 13
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 12
229910052749 magnesium Inorganic materials 0.000 claims abstract description 12
239000011777 magnesium Substances 0.000 claims abstract description 12
239000000126 substance Substances 0.000 claims abstract description 11
239000013543 active substance Substances 0.000 claims abstract description 4
239000003380 propellant Substances 0.000 claims description 91
150000001875 compounds Chemical class 0.000 claims description 82
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 66
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 57
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 52
150000003839 salts Chemical class 0.000 claims description 43
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 42
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 41
235000019359 magnesium stearate Nutrition 0.000 claims description 33
239000001272 nitrous oxide Substances 0.000 claims description 28
229910002092 carbon dioxide Inorganic materials 0.000 claims description 26
239000001569 carbon dioxide Substances 0.000 claims description 26
229960002714 fluticasone Drugs 0.000 claims description 23
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 23
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 22
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 21
229960004436 budesonide Drugs 0.000 claims description 21
239000002245 particle Substances 0.000 claims description 21
229960002052 salbutamol Drugs 0.000 claims description 21
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 20
229960002848 formoterol Drugs 0.000 claims description 20
239000007788 liquid Substances 0.000 claims description 20
231100000252 nontoxic Toxicity 0.000 claims description 17
230000003000 nontoxic effect Effects 0.000 claims description 17
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 16
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 16
229940125388 beta agonist Drugs 0.000 claims description 16
229960001022 fenoterol Drugs 0.000 claims description 16
229940063002 magnesium palmitate Drugs 0.000 claims description 16
ABSWXCXMXIZDSN-UHFFFAOYSA-L magnesium;hexadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O ABSWXCXMXIZDSN-UHFFFAOYSA-L 0.000 claims description 16
229960004017 salmeterol Drugs 0.000 claims description 16
239000012439 solid excipient Substances 0.000 claims description 16
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 15
229960000195 terbutaline Drugs 0.000 claims description 15
NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 14
229950008204 levosalbutamol Drugs 0.000 claims description 14
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 14
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 13
-1 triamicinolone Chemical compound 0.000 claims description 13
239000004094 surface-active agent Substances 0.000 claims description 12
OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims description 11
239000008116 calcium stearate Substances 0.000 claims description 11
235000013539 calcium stearate Nutrition 0.000 claims description 11
229960000193 formoterol fumarate Drugs 0.000 claims description 11
229960001664 mometasone Drugs 0.000 claims description 11
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 11
229940012185 zinc palmitate Drugs 0.000 claims description 11
GJAPSKMAVXDBIU-UHFFFAOYSA-L zinc;hexadecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O GJAPSKMAVXDBIU-UHFFFAOYSA-L 0.000 claims description 11
NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 claims description 10
HRBZRZSCMANEHQ-UHFFFAOYSA-L calcium;hexadecanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O HRBZRZSCMANEHQ-UHFFFAOYSA-L 0.000 claims description 10
229960002462 glycopyrronium bromide Drugs 0.000 claims description 10
229940078456 calcium stearate Drugs 0.000 claims description 9
229940057948 magnesium stearate Drugs 0.000 claims description 9
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 9
229940110309 tiotropium Drugs 0.000 claims description 9
229940057977 zinc stearate Drugs 0.000 claims description 9
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 8
ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims description 8
229960003728 ciclesonide Drugs 0.000 claims description 8
229960001888 ipratropium Drugs 0.000 claims description 8
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 8
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 7
229950004432 rofleponide Drugs 0.000 claims description 7
KYNQOULUPYDEMV-ITSONIETSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 KYNQOULUPYDEMV-ITSONIETSA-N 0.000 claims description 6
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 6
229960002576 amiloride Drugs 0.000 claims description 6
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 6
229940092705 beclomethasone Drugs 0.000 claims description 6
229960001117 clenbuterol Drugs 0.000 claims description 6
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 6
MCKJPJYRCPANCC-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 MCKJPJYRCPANCC-XLXYOEISSA-N 0.000 claims description 5
229960000676 flunisolide Drugs 0.000 claims description 5
229960001798 loteprednol Drugs 0.000 claims description 5
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
150000001735 carboxylic acids Chemical class 0.000 claims description 4
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 3
239000007787 solid Substances 0.000 abstract description 4
230000005226 mechanical processes and functions Effects 0.000 abstract description 3
239000002671 adjuvant Substances 0.000 abstract 1
238000005259 measurement Methods 0.000 description 14
239000002904 solvent Substances 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
238000000034 method Methods 0.000 description 9
229910052782 aluminium Inorganic materials 0.000 description 8
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
238000011049 filling Methods 0.000 description 8
239000007921 spray Substances 0.000 description 8
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000006184 cosolvent Substances 0.000 description 6
239000007789 gas Substances 0.000 description 6
150000005828 hydrofluoroalkanes Chemical class 0.000 description 6
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
239000010419 fine particle Substances 0.000 description 5
238000000265 homogenisation Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000007789 sealing Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 4
229960005294 triamcinolone Drugs 0.000 description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
BNPSSFBOAGDEEL-NMFAMCKASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-NMFAMCKASA-N 0.000 description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
239000005642 Oleic acid Substances 0.000 description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
239000004147 Sorbitan trioleate Substances 0.000 description 3
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 3
150000001335 aliphatic alkanes Chemical class 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000008021 deposition Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000001282 iso-butane Substances 0.000 description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
235000021313 oleic acid Nutrition 0.000 description 3
229960002969 oleic acid Drugs 0.000 description 3
239000001294 propane Substances 0.000 description 3
235000019337 sorbitan trioleate Nutrition 0.000 description 3
229960000391 sorbitan trioleate Drugs 0.000 description 3
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 description 2
AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000001273 butane Substances 0.000 description 2
150000001734 carboxylic acid salts Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
229960001037 fenoterol hydrobromide Drugs 0.000 description 2
FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229960001361 ipratropium bromide Drugs 0.000 description 2
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 2
229960005105 terbutaline sulfate Drugs 0.000 description 2
229960000257 tiotropium bromide Drugs 0.000 description 2
238000009736 wetting Methods 0.000 description 2
RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
230000009194 climbing Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
150000001983 dialkylethers Chemical class 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
238000005188 flotation Methods 0.000 description 1
WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
229940125389 long-acting beta agonist Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960000797 oxitropium Drugs 0.000 description 1
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000008249 pharmaceutical aerosol Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
SVETUDAIEHYIKZ-IUPFWZBJSA-N tris[(z)-octadec-9-enyl] phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP(=O)(OCCCCCCCC\C=C/CCCCCCCC)OCCCCCCCC\C=C/CCCCCCCC SVETUDAIEHYIKZ-IUPFWZBJSA-N 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
MPLUJWVUQCBCBX-UHFFFAOYSA-L zinc;16-methylheptadecanoate Chemical compound [Zn+2].CC(C)CCCCCCCCCCCCCCC([O-])=O.CC(C)CCCCCCCCCCCCCCC([O-])=O MPLUJWVUQCBCBX-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dispersion Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NO20034323A 2001-03-30 2003-09-26 Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer. NO332848B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH6012001		2001-03-30
CH15272001		2001-08-20
PCT/CH2002/000145 WO2002078671A1 (de)	2001-03-30	2002-03-11	Medizinische aerosolformulierungen

Publications (3)

Publication Number	Publication Date
NO20034323L NO20034323L (no)	2003-09-26
NO20034323D0 NO20034323D0 (no)	2003-09-26
NO332848B1 true NO332848B1 (no)	2013-01-21

Family

ID=25737693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20034323A NO332848B1 (no)	2001-03-30	2003-09-26	Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer.

Country Status (23)

Country	Link
US (1)	US20040101483A1 (sk)
EP (1)	EP1372608B1 (sk)
JP (1)	JP4824267B2 (sk)
CN (1)	CN100496608C (sk)
AT (1)	ATE375142T1 (sk)
AU (1)	AU2002234476B2 (sk)
CA (1)	CA2442415C (sk)
CY (1)	CY1107128T1 (sk)
CZ (1)	CZ301676B6 (sk)
DE (1)	DE50211045D1 (sk)
DK (1)	DK1372608T3 (sk)
ES (1)	ES2292713T3 (sk)
HK (1)	HK1064295A1 (sk)
HU (1)	HU229798B1 (sk)
NO (1)	NO332848B1 (sk)
NZ (1)	NZ528640A (sk)
PL (1)	PL207377B1 (sk)
PT (1)	PT1372608E (sk)
RO (1)	RO121172B1 (sk)
RU (1)	RU2294737C2 (sk)
SK (1)	SK286394B6 (sk)
WO (1)	WO2002078671A1 (sk)
ZA (1)	ZA200307161B (sk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070212422A1 (en) *	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
WO2003024396A2 (en)	2001-09-17	2003-03-27	Glaxo Group Limited	Dry powder medicament formulations
GB0208609D0 (en) *	2002-04-13	2002-05-22	Glaxo Group Ltd	Compositions
KR20050088307A (ko) *	2002-12-10	2005-09-05	세프라코 아이엔시.	레발부테롤 염
EP1646370A1 (en) *	2003-07-11	2006-04-19	Glaxo Group Limited	Pharmaceutical formulations
GB0316335D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Pharmaceutical formulations
GB0323685D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0323684D0 (en)	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0324918D0 (en) *	2003-10-24	2003-11-26	Glaxo Group Ltd	Composition
NZ548302A (en) *	2004-02-06	2010-04-30	Meda Pharma Gmbh & Co Kg	Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
SI1713471T1 (sl)	2004-02-06	2012-07-31	Meda Pharma Gmbh & Co Kg	Kombinacija antiholinergikov in inhibitorjev fosfodiesteraze tipa za zdravljenje respiratornih bolezni
ES2413011T3 (es)	2004-02-06	2013-07-15	Meda Pharma Gmbh & Co. Kg	Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
GB0409703D0 (en) *	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0426301D0 (en) *	2004-11-30	2004-12-29	Vectura Ltd	Pharmaceutical formulations
GB0501956D0 (en) *	2005-01-31	2005-03-09	Arrow Internat	Nebulizer formulation
RU2420285C2 (ru)	2005-03-16	2011-06-10	Меда Фарма Гмбх Унд Ко.Кг	Комбинация r,r-гликопирролата и монтелукаста для лечения респираторных заболеваний и фармацевтическая композиция на ее основе
ATE529399T1 (de)	2005-11-10	2011-11-15	Nicholas S Bodor	Sanfte anticholinerge ester
DE602006008665D1 (de)	2005-12-21	2009-10-01	Meda Pharma Gmbh & Co Kg	Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
AU2012200449B2 (en) *	2005-12-21	2013-07-25	Meda Pharma Gmbh & Co Kg	Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0602897D0 (en) *	2006-02-13	2006-03-22	Jagotec Ag	Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
GB0625303D0 (en) *	2006-12-19	2007-01-24	Jagotec Ag	Improvements in and relating to metered dose inhalers
LT2435025T (lt) *	2009-05-29	2016-09-26	Pearl Therapeutics, Inc.	Veikliosios medžiagos tiekimas per kvėpavimo takus
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) *	2009-05-29	2017-07-27	Pearl Therapeutics, Inc.	Respiratory delivery of active agents
AU2015201864A1 (en) *	2009-05-29	2015-04-30	Pearl Therapeutics, Inc.	Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
GB0918149D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved medicinal aerosol formulation
GB0918150D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved formulations
PE20160853A1 (es)	2009-12-23	2016-09-14	Chiesi Farm Spa	Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
KR20120106753A (ko) *	2009-12-23	2012-09-26	키에시 파르마슈티시 엣스. 피. 에이.	Ｃｏｐｄ용 에어로졸 제제
MX340264B (es) *	2009-12-23	2016-07-04	Chiesi Farm Spa	Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
JP5513177B2 (ja) *	2010-03-08	2014-06-04	共同印刷株式会社	湿度インジケータとその製造方法、該製造方法に用いる湿度インジケータ用塗料
CN102416179B (zh)	2010-09-28	2014-05-07	益得生物科技股份有限公司	用于哮喘的吸入性复方组合物
WO2013053696A1 (en)	2011-10-11	2013-04-18	Chiesi Farmaceutici S.P.A.	Crystalline microparticles of a beta-agonist coated with a fatty acid
CN102362860A (zh) *	2011-10-27	2012-02-29	江阴长风医药科技有限公司	以氢氟烷烃为抛射剂的布***和福莫特罗气雾剂制剂
KR102391332B1 (ko)	2013-03-15	2022-04-26	펄 테라퓨틱스 인코포레이티드	미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
WO2017178966A1 (en) *	2016-04-11	2017-10-19	Suven Life Sciences Limited	Topical spray formulation of glycopyrrolate

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55361B1 (sk) *	1970-09-17	1980-01-08
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
US5874063A (en) *	1991-04-11	1999-02-23	Astra Aktiebolag	Pharmaceutical formulation
EP0561166A1 (de) *	1992-03-17	1993-09-22	ASTA Medica Aktiengesellschaft	Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
MX9304585A (es) *	1992-07-31	1994-03-31	Glaxo Group Ltd	Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH06135815A (ja) *	1992-10-30	1994-05-17	Shiseido Co Ltd	経皮吸収抑制組成物
ZA939195B (en) *	1992-12-09	1995-06-08	Boehringer Ingelheim Pharma	Stabilized medicinal aerosol solution formulations
DE4321288A1 (de) *	1993-06-26	1995-01-05	Solvay Fluor & Derivate	Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
ATE233544T1 (de) *	1993-12-02	2003-03-15	Abbott Lab	Aerosole als darreichungsform mit cfc-freiem treibmittel
US5589156A (en) *	1994-05-02	1996-12-31	Henry; Richard A.	Prilocaine and hydrofluourocarbon aerosol preparations
US6524557B1 (en) *	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
CA2206782C (en) *	1994-12-22	2007-04-03	Astra Aktiebolag	Aerosol drug formulations
JP3707107B2 (ja) *	1995-09-18	2005-10-19	鈴木油脂工業株式会社	薬剤分散液及びその製造方法
US6054488A (en) *	1996-06-11	2000-04-25	3M Innovative Properties Company	Medicinal aerosol formulations of formoterol
US6261472B1 (en) *	1996-11-04	2001-07-17	E. I. Du Pont De Nemours And Company	Azeotrope-like compositions containing fluoroethane
US6361938B1 (en) *	1996-11-08	2002-03-26	Elan Corporation, Plc	Peptides which enhance transport across tissues and methods of identifying and using the same
ATE290368T1 (de) *	1997-01-30	2005-03-15	Alltracel Dev Services Ltd	Blutstillende aerosol-zubereitung
WO1998034595A1 (de) *	1997-02-05	1998-08-13	Jago Research Ag	Medizinische aerosolformulierungen
US6086376A (en) *	1998-01-30	2000-07-11	Rtp Pharma Inc.	Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) *	1998-06-19	2002-09-17	Baker Norton Pharmaceuticals, Inc.	Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) *	1998-07-24	2004-12-15	Jago Res Ag	Medizinische aerosolformulierungen
US6475467B1 (en) *	1998-08-04	2002-11-05	Jago Research Ag	Medicinal aerosol formulations
US7521068B2 (en) *	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) *	1998-12-22	2005-08-09	The University Of North Carolina At Chapel Hill	Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9903759D0 (en) *	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
DZ3358A1 (fr) *	2000-05-22	2001-11-29	Chiesi Farma Spa	Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
US20060257324A1 (en) *	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
US20020076382A1 (en) *	2000-08-04	2002-06-20	Kaplan Leonard W.	Formulations of mometasone and a bronchodilator for pulmonary administration
DK2283818T3 (en) *	2000-11-30	2017-10-16	Vectura Ltd	Process for preparing particles for use in a pharmaceutical composition
TWI324934B (en) *	2001-08-28	2010-05-21	Schering Corp	Pharmaceutical compositions for the treatment of asthma
JP2005523905A (ja) *	2002-03-01	2005-08-11	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
US7582284B2 (en) *	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
GB0323685D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0323684D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0918150D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved formulations
GB0918149D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved medicinal aerosol formulation

2002
- 2002-03-11 AU AU2002234476A patent/AU2002234476B2/en not_active Ceased
- 2002-03-11 RO ROA200300799A patent/RO121172B1/ro unknown
- 2002-03-11 RU RU2003131676/15A patent/RU2294737C2/ru not_active IP Right Cessation
- 2002-03-11 DE DE50211045T patent/DE50211045D1/de not_active Expired - Lifetime
- 2002-03-11 AT AT02701145T patent/ATE375142T1/de active
- 2002-03-11 DK DK02701145T patent/DK1372608T3/da active
- 2002-03-11 EP EP02701145A patent/EP1372608B1/de not_active Expired - Lifetime
- 2002-03-11 CN CNB028073827A patent/CN100496608C/zh not_active Expired - Fee Related
- 2002-03-11 NZ NZ528640A patent/NZ528640A/en not_active IP Right Cessation
- 2002-03-11 ES ES02701145T patent/ES2292713T3/es not_active Expired - Lifetime
- 2002-03-11 CA CA2442415A patent/CA2442415C/en not_active Expired - Fee Related
- 2002-03-11 HU HU0401250A patent/HU229798B1/hu not_active IP Right Cessation
- 2002-03-11 SK SK1334-2003A patent/SK286394B6/sk not_active IP Right Cessation
- 2002-03-11 CZ CZ20032915A patent/CZ301676B6/cs not_active IP Right Cessation
- 2002-03-11 US US10/473,874 patent/US20040101483A1/en not_active Abandoned
- 2002-03-11 PL PL362797A patent/PL207377B1/pl unknown
- 2002-03-11 JP JP2002576937A patent/JP4824267B2/ja not_active Expired - Fee Related
- 2002-03-11 PT PT02701145T patent/PT1372608E/pt unknown
- 2002-03-11 WO PCT/CH2002/000145 patent/WO2002078671A1/de active IP Right Grant
2003
- 2003-09-12 ZA ZA2003/07161A patent/ZA200307161B/en unknown
- 2003-09-26 NO NO20034323A patent/NO332848B1/no not_active IP Right Cessation
2004
- 2004-09-17 HK HK04107112.4A patent/HK1064295A1/xx not_active IP Right Cessation
2008
- 2008-01-08 CY CY20081100021T patent/CY1107128T1/el unknown

Also Published As

Publication number	Publication date
CZ20032915A3 (en)	2004-06-16
HUP0401250A2 (hu)	2004-11-29
AU2002234476B2 (en)	2006-04-27
NO20034323L (no)	2003-09-26
AU2002234476C1 (en)	2002-10-15
ES2292713T3 (es)	2008-03-16
CN1499958A (zh)	2004-05-26
EP1372608B1 (de)	2007-10-10
US20040101483A1 (en)	2004-05-27
SK286394B6 (sk)	2008-09-05
HUP0401250A3 (en)	2008-04-28
NZ528640A (en)	2004-06-25
PL207377B1 (pl)	2010-12-31
JP2004525148A (ja)	2004-08-19
RU2294737C2 (ru)	2007-03-10
SK13342003A3 (sk)	2004-08-03
RO121172B1 (ro)	2007-01-30
CZ301676B6 (cs)	2010-05-19
HU229798B1 (en)	2014-07-28
NO20034323D0 (no)	2003-09-26
CN100496608C (zh)	2009-06-10
DE50211045D1 (de)	2007-11-22
PT1372608E (pt)	2008-01-04
DK1372608T3 (da)	2007-12-27
HK1064295A1 (en)	2005-01-28
WO2002078671A1 (de)	2002-10-10
PL362797A1 (en)	2004-11-02
JP4824267B2 (ja)	2011-11-30
CY1107128T1 (el)	2012-10-24
EP1372608A1 (de)	2004-01-02
CA2442415A1 (en)	2002-10-10
ATE375142T1 (de)	2007-10-15
ZA200307161B (en)	2005-01-26
RU2003131676A (ru)	2005-02-10
CA2442415C (en)	2010-07-20

Legal Events

Date	Code	Title	Description
2018-10-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
AU2002234476B2 (en)	2006-04-27	Medical aerosol formulations
US6475467B1 (en)	2002-11-05	Medicinal aerosol formulations
JP4570251B2 (ja)	2010-10-27	医薬用エーロゾル製剤
JP3675474B2 (ja)	2005-07-27	医薬
CA2280099C (en)	2005-12-27	Medical aerosol formulations
EP0536250B1 (en)	2000-09-06	Aerosol drug formulations
AU658854B2 (en)	1995-05-04	Aerosol formulation comprising beclomethasone 17,21 dipropionate
AU670616B2 (en)	1996-07-25	Surfactant free aerosol formulations containing beclomethasone dipropionate
US5635159A (en)	1997-06-03	Aerosol drug formulations containing polyglycolyzed glycerides
US20070256685A1 (en)	2007-11-08	Aerosol Formulations Comprising Formoterol Fumarate Dihydrate
KR20100004993A (ko)	2010-01-13	안정한 약제학적 약물 에어로졸
KR0175164B1 (ko)	1999-02-01	에어로졸 약물 제제
SG178764A1 (en)	2012-03-29	Stable pharmaceutical drug aerosols